Skip to main content
Premium Trial:

Request an Annual Quote

Agilent, BioTek Partner on Cellular Metabolic Analysis, Imaging

NEW YORK (GenomeWeb) – Agilent Technologies and BioTek Instruments have partnered to develop an integrated product for cellular metabolic analysis and imaging.

Specifically, the companies will integrate Agilent's Seahorse XFe96/XFe24 Analyzers with BioTek's Cytation 1 Cell Imaging Multi-Mode Reader. The combined product will enable a standardized approach to compare XF data sets, improve assay workflow, embed images into WAVE software, and apply normalization values to Seahorse XF measurements.

Agilent Seahorse XFe Analyzers simultaneously measure the two major cellular energy-producing pathways — mitochondrial respiration and glycolysis — in live cells in real time. These measurements help scientists to better understand the connection between cellular physiological processes, and genomic and proteomic data. 

"Agilent's automated XFe Analyzers, combined with BioTek's Cytation 1 Cell Imaging Multi-Mode Reader, creates a distinct opportunity for cell biology researchers to fully normalize and analyze samples to answer challenging questions regarding cellular metabolism," Gary Barush, global director of marketing and sales at BioTek.

"Agilent customers requested an optimized method for verifying assay results, and enabling more meaningful data comparisons provided by our data-rich assays," added David Ferrick, senior director of Agilent's cell analysis division. "This integrated solution gives our customers the ability to compare XF data on a well-to-well, plate-to-plate, and experiment-to-experiment basis."

The companies will jointly market the integrated product in the US and Europe beginning this month and worldwide by June.